Veradermics, Inc (MANE)
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Veradermics, Incorporated
No splits on record
Nothing in MANE's public trading history: no forward or reverse split has affected the share count.
| Period | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Currency | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
| Revenue | $0 | $0 | $0 |
| YoY Growth | - | - | - |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Gross Margin | - | - | - |
| Research and Development | $62.06M | $23.28M | $14.97M |
| Selling, General, and Administrative | $10.28M | $3.5M | $2.35M |
| Other | $0 | $0 | $0 |
| Total Operating Expenses | $72.35M | $26.78M | $17.32M |
| Operating Income (EBIT) | -$72.35M | -$26.78M | -$17.32M |
| Operating Margin | - | - | - |
| Interest Expense | $0 | $585K | $36K |
| Interest Income | $1.56M | $481K | $870K |
| Other Income (Expense) | $2.35M | $290K | $834K |
| Income Before Tax (EBT) | -$70M | -$26.49M | -$16.49M |
| Income Tax Expense | $0 | $0 | $0 |
| Net Income | -$70M | -$26.49M | -$16.49M |
| Net Income Margin | - | - | - |
| Supplementary Data | |||
| EPS | -2.38 | -0.14 | -0.08 |
| Diluted EPS | -2.38 | -0.14 | -0.08 |
| Weighted Average OS | 35.08M | 201.33M | 201.33M |
| EBITDA | -$70M | -$25.9M | -$16.45M |
| EBITDA Margin | - | - | - |
| Period | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Currency | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
| Assets | |||
| Current Assets | |||
| Cash and Cash Equivalents | $21.77M | $53.08M | $16.3M |
| Short-Term Investments | $120.1M | $0 | $0 |
| Cash and Short-Term Investments | $141.86M | $53.08M | $16.3M |
| Accounts Receivable | $1.25M | $1.38M | $0 |
| Inventory | $0 | $0 | $0 |
| Other Current Assets | $3.77M | $38K | $46K |
| Total Current Assets | $152.49M | $55.53M | $17.56M |
| Long-Term Assets | |||
| Property, Plant & Equipment Net | $125K | $0 | $0 |
| Goodwill | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 |
| Long-Term Investments | $0 | $3.85M | $894K |
| Deferred Tax Assets | $0 | $0 | $0 |
| Other Long-Term Assets | $0 | $0 | -$1 |
| Total Long-Term Assets | $125K | $3.85M | $894K |
| Other Assets | $0 | $0 | $1 |
| Total Assets | $152.62M | $59.38M | $18.46M |
| Liabilities | |||
| Current Liabilities | |||
| Accounts Payable | $2.13M | $2.25M | $1.85M |
| Short-Term Debt | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 |
| Other Current Liabilities | $47K | $1.44M | $436K |
| Total Current Liabilities | $9.15M | $4.72M | $3.05M |
| Long-Term Liabilities | |||
| Long-Term Debt | $0 | $0 | $786K |
| Long-Term Unearned Revenue | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 |
| Other Long-Term Liabilities | $264.48M | $0 | $0 |
| Total Long-Term Liabilities | $264.48M | $0 | $786K |
| Other Liabilities | $0 | $0 | $0 |
| Total Liabilities | $273.63M | $4.72M | $3.84M |
| Stockholders' Equity | |||
| Preferred Stock | $0 | $103.14M | $36.86M |
| Common Stock | $1K | $1K | $1K |
| Retained Earnings | -$123.42M | -$49.23M | -$22.74M |
| Comprehensive Income & Other | $60K | $0 | $0 |
| Other Stockholders' Equity | $2.41M | $103.89M | $37.36M |
| Total Equity | -$121.01M | $54.66M | $14.62M |
| Minority Interest | $0 | $0 | $0 |
| Total Liabilities and Equity | $152.62M | $59.38M | $18.46M |
| Supplementary Data | |||
| Total Debt | $4K | $0 | $786K |
| Net Debt | -$21.76M | -$53.08M | -$15.51M |
| Period | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Currency | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
| Operating Activities | |||
| Net Income | -$70M | -$26.49M | -$16.49M |
| Depreciation & Amortization | $0 | $0 | $0 |
| Deferred Income Tax | $0 | $0 | $0 |
| Stock-Based Compensation | $1.44M | $250K | $206K |
| Changes in Working Capital: | |||
| Accounts Receivable | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 |
| Accounts Payable | -$122K | $646K | $1.35M |
| Other Working Capital | -$3.76M | $86K | -$434K |
| Total Working Capital Change | -$3.89M | $732K | $920K |
| Other Non-Cash Items | $839K | $1.82M | $1.85M |
| Net Cash from Operating | -$71.6M | -$23.69M | -$13.51M |
| Investing Activities | |||
| Capital Expenditures | -$24K | $0 | $0 |
| Acquisitions | $0 | $0 | $0 |
| Purchases of Investments | -$143.85M | $0 | $0 |
| Sales of Investments | $25.02M | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 |
| Net Cash from Investing | -$118.86M | $0 | $0 |
| Financing Activities | |||
| Debt Repaid | - | -$7.66M | - |
| Common Stock Issuance | $156K | $52.81M | $0 |
| Common Stock Repurchases | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 |
| Other Financing Activities | -$447K | $0 | -$35K |
| Net Cash from Financing | $159.14M | $60.48M | $13.89M |
| Forex Effect | $0 | $0 | $0 |
| Net Change in Cash | -$31.32M | $36.79M | $385K |
| Supplementary Data | |||
| Operating Cash Flow | -$71.6M | -$23.69M | -$13.51M |
| Capital Expenditure | -$24K | $0 | $0 |
| Free Cash Flow | -$71.63M | -$23.69M | -$13.51M |
| Cash at Beginning | $53.08M | $16.3M | $15.91M |
| Cash at End | $21.77M | $53.08M | $16.3M |